Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC
Clinical trial NCT04425135 · UNKNOWN
Trial details
- NCT number
- NCT04425135
- Sponsor
- The First Affiliated Hospital of Xiamen University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-01
- Primary completion
- 2023-01-01
- Enrollment
- 59
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.